There&#x27;s a paper in the Clinical Chemistry and Laboratory Medicine journal titled, &quot;Theranos phenomenon: promises and fallacies&quot; [1]. It says most of the cost are related to overhead and personnel, not technology. Consumables are cheap. Also it is entirely possible that tests are being subsidized with VC money currently. I don&#x27;t know what they would have to charge to be cash flow positive.<p>[1] <a href="http:&#x2F;&#x2F;www.degruyter.com&#x2F;view&#x2F;j&#x2F;cclm.2015.53.issue-7&#x2F;cclm-2015-0356&#x2F;cclm-2015-0356.xml#.Vh9SBB1M8fo.twitter" rel="nofollow">http:&#x2F;&#x2F;www.degruyter.com&#x2F;view&#x2F;j&#x2F;cclm.2015.53.issue-7&#x2F;cclm-20...</a>